Buy these 4 ASX 300 shares, say top brokers

Market analysts have upgraded their ratings on these four ASX 300 shares today.

| More on:
A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

S&P/ASX 300 Index (ASX: XKO) shares are having a belter with the index up 1.46% to 7,058.6 points.

The strong daily gain comes amid new United States inflation data released overnight.

Headline US inflation declined to 3.2% for the 12 months to October, down from 3.7% over the past two months.

Core inflation, which excludes volatile items like energy and food, came in at its lowest level in two years at 4%. These numbers could signal the end of interest rate hikes in the world's biggest economy.

Amid this news, brokers have upgraded the following four ASX 300 shares (courtesy The Australian).

CSL Limited (ASX: CSL)

The CSL share price is currently $259.98, up 2.5% at the time of writing. Top broker Goldman Sachs says the blue-chip ASX 300 biotech share is now at a "compelling entry point after [a] multiple de-rate". It has upgraded CSL to a buy rating with a 12-month share price target of $309, implying a 19% potential upside. Goldman's price target is conservative compared to other top brokers, with the most bullish being UBS, with its target of $340 per share. Ellerston Capital portfolio manager, Chris Kourtis says the CSL share price has been "absolutely pulverised" and is a great buy-the-dip opportunity for investors today.

Clinuvel Pharmaceuticals Limited (ASX: CUV)

The Clinuvel share price is $16.53, up 3.3% so far today. Morgans has commenced coverage of the ASX 300 healthcare share with an add rating and a $22 share price target. If Morgans has it right, investors could be set for a 33% gain in just 12 months. Clinuvel released a new presentation regarding its phase three vitiligo treatment program last Friday.

ALS Ltd (ASX: ALQ)

The ALS share price is $12.03, up 3.8% so far today. Jefferies has upgraded the ASX 300 industrial share to a buy rating with a $13.20 share price target. This implies a potential upside of just under 10%. The testing solutions company reported an underlying net profit after tax (NPAT) of $158 million and a partially franked interim dividend of 19.6 cents per share for the 1H FY24 period yesterday.

Maas Group Holdings Ltd (ASX: MGH)

The Maas Group share price is $3.57, down 0.56% today. Also an ASX 300 industrial share, Maas Group has attracted a buy rating from Jefferies. The broker has commenced coverage with a $4.25 target. This means investors who buy today could enjoy a 19% upside over the next 12 months. CEO and managing director Wes Maas discussed FY24 guidance at the AGM in late October, telling investors the company expected proforma earnings before interest, taxes, depreciation, and amortisation (EBITDA) in the range of $190 million to $210 million.

Motley Fool contributor Bronwyn Allen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Cheerful businessman with a mining hat on the table sitting back with his arms behind his head while looking at his laptop's screen.
Broker Notes

Macquarie tips 50% upside for this ASX 200 miner, and it's not BHP!

Unheralded miner poised to surge?

Read more »

A woman sits on sofa pondering a question.
Broker Notes

Guess which ASX All Ords media stock Macquarie expects to rise 17% over the next 12 months?

The broker is expecting big things from this media company.

Read more »

A couple stares at the tv in shock, one holding the remote up ready to press.
Broker Notes

These ASX 200 shares could rise 20% to 35%

Let's see why these shares are being tipped to rise strongly from where they trade.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Up 110% in 12 months: Why this ASX 200 stock can keep flying

Let's see what Bell Potter is saying about this high-flyer.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man in a dark blue suit walks through an airport past floor-to-ceiling windows with a Qantas plane flying in the distance
Travel Shares

Up 16% this year, does Macquarie rate Corporate Travel Management shares a buy, hold or sell?

Does the travel stock have further to fly?

Read more »

group of friends checking facebook on their smartphones
Broker Notes

Macquarie tips 22% return for this ASX telco stock

This telco could be undervalued at current levels according to the broker.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »